[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619025":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":10,"locations":26,"responsibleParty":56,"collaborators":58,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Southern California","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients complete surveys on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Non-Interventional Study","Non-interventional study",[9],[20,21],"Non-Interventional Observational Study","Noninterventional (Observational) Study",[23],{"name":24,"affiliation":5,"role":25},"Robert Hsu","PRINCIPAL_INVESTIGATOR",[27,48],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Los Angeles General Medical Center","RECRUITING","Los Angeles","California","90033","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-118.24368,34.05223,{"lat":39,"lon":38},[42,47],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Sandy Tran","CONTACT","323-865-3000","sandy.tran@med.usc.edu",{"name":24,"role":25,"phone":10,"phoneExt":10,"email":10},{"facility":49,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":50,"geoPoint":52,"contacts":53},"USC \u002F Norris Comprehensive Cancer Center",{"type":36,"coordinates":51},[38,39],{"lat":39,"lon":38},[54,55],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},{"name":24,"role":25,"phone":10,"phoneExt":10,"email":10},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[59,62],{"name":60,"class":61},"National Cancer Institute (NCI)","NIH",{"name":63,"class":64},"Bristol-Myers Squibb","INDUSTRY","100619025","experiences-w--attitudes-towards-immune-chckpt-inhibitors-in-nsclc-patients-single-center-survey-based-study-100619025",false,"NCT07339254","Experiences w\u002F & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study","Experiences With and Attitudes Towards Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer (NSCLC) - A Single Center, Survey-Based Study","Inclusion Criteria:\n\n* \\* Age ≥ 18 years.\n* \\* Patients must have histopathologically\u002Fcytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)\n* \\* Previous chemotherapy\u002Fradiotherapy\u002Ftargeted\u002Fimmunotherapy is allowed at any prior timepoint.\n* \\* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.\n\nExclusion Criteria:\n\n* \\* Patients is unable to consent for themselves\n* \\* Patient has not yet completed the 1st cycle of ICI-based therapy","ALL","18 Years",{"count":75,"type":76},40,"ESTIMATED","OBSERVATIONAL","This study evaluates patient satisfaction with receiving intravenous (IV) and\u002For subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.",[80],"Lung Non-Small Cell Carcinoma","2026-03-13",{"date":83,"type":84},"2026-03-16","ACTUAL",{"date":86,"type":84},"2026-03-12",{"date":88,"type":76},"2028-03-12",{"name":5,"class":6},2]